Customer scenarios

1. JAMA. Impotence. NIH consensus development panel on impotence. 1993, Jul.
Available at: https://jamanetwork.com/journals/jama/article-abstract/407163

2. NICE Clinical Knowledge Summary. Erectile dysfunction. 2024, Oct. Available at: https://cks.nice.org.uk/topics/erectile-dysfunction/

3. BNF. Erectile dysfunction. 2025. Available at: https://bnf.nice.org.uk/treatment-summaries/erectile-dysfunction/

4. Goldstein I, et al. Epidemiology update of erectile dysfunction in eight countries with high burden. Sex Med Rev 2020; 8:48e58.

5. Capogrosso P et al. One patient out of four with newly diagnosed erectile dysfunction is a young man – worrisome picture from the everyday clinical practice. J Sex Med 2013; 10:1833–1841.

6. Pharmacy Guide for AVARANTE 10mg film coated tablets (tadalafil). 2024. Available at: https://www.medicines.org.uk/emc/rmm/101574/Document

7. McCabe MP, Althof SE. A systematic review of the psychosocial outcomes associated with erectile dysfunction: Does the impact of erectile dysfunction extend beyond a man’s inability to have sex? J Sex Med 2014;11:347-363.

8. Yafi FA, et al. Erectile dysfunction. Nat Rev Dis Primers. 2017; 2:16003. doi:10.1038/nrdp.2016.3

9. Bai W-J, et al. A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction. Asian J Androl 2017; 19:500–504.

10. Li H-J, et al. An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction. Asian J Androl. 2016; 18(5):773-779.

11. The British Association of Urological Surgeons. Erectile dysfunction. Frequently asked questions. 2024.
Available at: https://www.baus.org.uk/patients/conditions/3/erectile

12. Lilly. Cialis® (tadalafil) tablets recommended for approval for the treatment of the signs and symptoms of benign prostatic hyperplasia in the European Union. 2012, Sep. Available at: https://investor.lilly.com/static-files/5205db72-d6cc-4047-9ad1-61658a53c385

13. AVARANTE 10mg tablet. SmPC. 2024. Available at: https://www.medicines.org.uk/emc/product/100210/smpc/print

14. Gong B, et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017; 49:1731–1740.

15. Hackett G, et al. British Society for Sexual Medicine. Guidelines on the management of erectile dysfunction in Men – 2017. J Sex Med. 2018; 15(4): 430-457. doi.org/10.1016/j.jsxm.2018.01.023

16. Hatzimouratidis K, et al. Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. Int J Impot Res. 2014; 26(6):223-229.

17. Seftel AD, et al. Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily. Int J Impot Res. 2009; 21:240–248.

18. Salonia A, et al. EAU Guidelines on sexual and reproductive health. 2024. Available at: https://d56bochluxqnz.cloudfront.net/documents/fullguideline/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2024_2024-05-23-101205_nmbi.pdf

19. VIAGRA CONNECT 50mg film-coated tablets. SmPC. 2024. Available at: https://www.medicines.org.uk/emc/product/8725

20. Essential information for the supply of VIAGRA CONNECT® 50 mg film-coated tablets (sildenafil). 2023.
Available at: https://www.medicines.org.uk/emc/rmm/1784/Document

21. American Heart Association. Classes of Heart Failure. 2023.
Available at: https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure

22. AVARANTE 10mg film-coated tablets (tadalafil) Pharmacist Checklist Quick Guide. 2024.
Available at: https://www.medicines.org.uk/emc/rmm/101578/Document

23. Syed, P. Sexual performance anxiety and erectile dysfunction: the link, the differences, the treatments. 2025
Available at: https://www.healthline.com/health/erectile-dysfunction/performance-anxiety-erectile-dysfunction

24. Ahmed NS. Tadalafil: 15 years’ journey in male erectile dysfunction and beyond. Drug Dev Res. 2019; 80:683–701.

Online references last accessed June 2025.

Presentation: Avarante 10mg tablets. Contains tadalafil

Indication: Erectile dysfunction in adult men

Dose and Administration: Men (including the elderly) 18 years of age or over: The recommended dose is one 10mg tablet taken at least 30 minutes prior to anticipated sexual activity. The maximum dosing frequency is once per day. Avarante is not recommended for continuous daily use.

Contraindications: Hypersensitivity to the active substance or to any of the excipients, co-administration with nitric oxide donors or nitrates, cardiac disease in patients where sexual activity is inadvisable, myocardial infarction within the last 90 days, unstable angina or angina during sexual intercourse, heart failure within 6 months, uncontrolled arrhythmia, hypotension (<90/50 mm Hg), uncontrolled hypertension, stroke within 6 months, non-arteritic anterior ischaemic optic neuropathy causing loss of vision in one eye, co-administration with guanylate cyclase simulators (e.g. riociguat), deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), women, those without erectile dysfunction and men under 18 years of age.

Warnings and Precautions: All men with erectile dysfunction should be advised to consult their doctor within 6 months for a clinical review of potential underlying conditions and risk factors associated with erectile dysfunction. If symptoms of erectile dysfunction have not improved after taking Avarante on several consecutive occasions or if their erectile dysfunction worsens patients should consult their doctor. Patients who experience erections lasting longer than 4 hours should seek immediate medical assistance. Patients should consult their doctor before taking Avarante if they have: undergone pelvic surgery or radical non-nerve sparing prostatectomy, known hereditary degenerative retinal disorders (e.g. retinitis pigmentosa), had coronary artery bypass surgery or angioplasty, asymptomatic controlled hypertension, mild valvular disease, severe renal impairment, severe hepatic insufficiency, previous diagnosis of uncontrolled hypertension, moderate to severe valvular disease, left ventricular dysfunction, hypertrophic obstructive cardiomyopathies or significant arrhythmia, increased susceptibility to vasodilators including those with left ventricular outflow obstructions (e.g. aortic stenosis) or those with the rare syndrome of multiple atrophy, sickle cell anaemia, multiple myeloma or leukaemia. Patients with cardiovascular disease should be advised that sexual activity carries a cardiac risk and if they experience chest pain during sexual activity they should refrain from any further sexual activity and seek medical attention immediately. Avarante is not recommended for patients who experience chest pain or breathlessness after light or moderate activity. Avarante contains lactose; patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Avarante. Avarante is not recommended to be taken concurrently with recreational drugs. Interactions: Nitrates, nitric oxide donors (nicorandil, molsidomine), doxazosin and other alpha 1 adrenergic blockers, antihypertensives, riociguat, 5-alpha reductase inhibitors (e.g. finasteride), theophylline, ethinylestradiol, terbutaline, alcohol, CYP3A4 inhibitors such as ketoconazole, itraconazole, erythromycin, clarithromycin, and grapefruit juice should be administered with caution as they may increase the incidence of adverse reactions. Inducers of CYP3A4 such as rifampicin, phenobarbital, phenytoin and carbamazepine may decrease plasma concentrations of tadalafil and decrease efficacy.

Pregnancy and breastfeeding: Avarante is not indicated for use in women.

Side Effects: Adverse events observed from spontaneous reporting and clinical trials: Common (≥1/100 and <1/10): Headache, flushing, nasal congestion, dyspepsia, back pain, myalgia, pain in extremity. Uncommon (≥1/1,000 and <1/100): Hypersensitivity reactions, dizziness, blurred vision, eye pain, tinnitus, tachycardia, palpitations, hypotension, hypertension, dyspnoea, epistaxis, abdominal pain, vomiting, nausea, gastro-oesophageal reflux, rash, haematuria, prolonged erections, chest pain, peripheral oedema, fatigue. Rare (≥1/10,000 and <1/1000): Angioedema, stroke (including haemorrhagic events), syncope, transient ischaemic attacks, migraine, seizures, transient amnesia, visual field defect, swelling of eyelids, conjunctival hyperaemia, non-arteritic anterior ischemic optic neuropathy, retinal vascular occlusion, sudden hearing loss, myocardial infarction, unstable angina pectoris, ventricular arrhythmia, urticaria, Stevens-Johnson syndrome, exfoliative dermatitis, hyperhydrosis, priapism, penile haemorrhage, haematospermia, facial oedema, sudden cardiac death.

 

RRP: 2 pack £11.99, 4 pack £21.99, 8 pack £37.99

Supply classification: P Product licence number: PLGB 46302/0243

Product licence holder: Mylan Products Ltd, Station Close, Potters Bar, Herts, EN6 1TL, UK

 

Document number: UK-AVT-2024-00028

Date of preparation: November 2024

 

Name of product: VIAGRA CONNECT^® 50 mg Film-coated Tablets

Active ingredient: Sildenafil

Product licence number: PL 50622/0063

Name and address of the product licence holder: Upjohn UK Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK

Supply classification: P

Indications: For erectile dysfunction in adult men.

Side Effects: The safety profile of VIAGRA is based on > 9,000 patients in > 70 double-blind placebo controlled clinical studies. The most commonly reported adverse reactions in clinical studies among sildenafil treated patients were headache, flushing, dyspepsia, nasal congestion, dizziness, nausea, hot flush, visual disturbance, cyanopsia and vision blurred. Adverse reactions from post marketing surveillance has been gathered covering an estimated period >10 years. Because not all adverse reactions are reported to the Marketing Authorisation Holder and included in the safety database, the frequencies of these reactions cannot be reliably determined. Very Common (≥ 1/10): Headache. Common (≥ 1/100 and <1/10): Dizziness, Visual colour distortions (Chloropsia, Chromatopsia, Cyanopsia, Erythropsia and Xanthopsia), Visual disturbance, Vision blurred, Flushing, Hot flush, Nasal congestion, Nausea, Dyspepsia. Uncommon (≥ 1/1,000 and <1/100): Rhinitis, Hypersensitivity; Somnolence; Hypoaesthesia, Lacrimation disorders (Dry eye, Lacrimal disorder and Lacrimation increased), Eye pain, Photophobia, Photopsia, Ocular hyperaemia, Visual brightness, Conjunctivitis, Vertigo, Tinnitus, Tachycardia, Palpitations, Hypertension, Hypotension, Epistaxis, Sinus congestion, Gastro Oesophagael reflux disease, Vomiting, Abdominal pain upper, Dry mouth, Rash, Myalgia, Pain in extremity, Haematuria, Chest pain, Fatigue, Feeling hot, Heart rate increased. Rare (≥ 1/10,000 and <1/1,000): Cerebrovascular accident, Transient ischaemic attack, Seizure, Seizure recurrence, Syncope, Non-arteritic anterior ischaemic optic neuropathy (NAION), Retinal vascular occlusion, Retinal haemorrhage, Arteriosclerotic retinopathy, Retinal disorder, Glaucoma, Visual field defect, Diplopia, Visual acuity reduced, Myopia, Asthenopia, Vitreous floaters, Iris disorder, Mydriasis, Halo vision, Eye oedema, Eye swelling, Eye disorder, Conjunctival hyperaemia, Eye irritation, Abnormal sensation in eye, Eyelid oedema, Scleral discoloration, Deafness, Sudden cardiac death, Myocardial infarction, Ventricular arrhythmia, Atrial fibrillation, Unstable angina, Throat tightness, Nasal oedema, Nasal dryness, Hypoaesthesia oral, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN),Penile haemorrhage, Priapism, Haematospermia, Erection increased, Irritability

Precautions: Erectile dysfunction can be associated with a number of contributing conditions, e.g. hypertension, diabetes mellitus, hypercholesterolaemia or cardiovascular disease. As a result, all men with erectile dysfunction should be advised to consult their doctor within 6 months for a clinical review of potential underlying conditions and risk factors associated with erectile dysfunction (ED). If symptoms of ED have not improved after taking VIAGRA CONNECT on several consecutive occasions, or if their erectile dysfunction worsens, the patient should be advised to consult their doctor.

Cardiovascular risk factors: Since there is a degree of cardiac risk associated with sexual activity, the cardiovascular status of men should be considered prior to initiation of therapy. Agents for the treatment of erectile dysfunction, including sildenafil, are not recommended to be used by those men who with light or moderate physical activity, such as walking briskly for 20 minutes or climbing 2 flights of stairs, feel very breathless or experience chest pain. The following patients are considered at low cardiovascular risk from sexual activity: patients who have been successfully revascularised (e.g. via coronary artery bypass grafting, stenting, or angioplasty), patients with asymptomatic controlled hypertension, and those with mild valvular disease. These patients may be suitable for treatment but should consult a doctor before resuming sexual activity.

Patients previously diagnosed with the following must be advised to consult with their doctor before resuming sexual activity: uncontrolled hypertension, moderate to severe valvular disease, left ventricular dysfunction, hypertrophic obstructive and other cardiomyopathies, or significant arrhythmias. Sildenafil has vasodilator properties, resulting in mild and transient decreases in blood pressure. Patients with increased susceptibility to vasodilators include those with left ventricular outflow obstruction (e.g., aortic stenosis), or those with the rare syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure. Men with these conditions must not use the product without consulting a doctor. Sildenafil potentiates the hypotensive effect of nitrates (see Contra-indications). Serious cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack, hypertension and hypotension have been reported post-marketing in temporal association with the use of sildenafil. Most, but not all, of these patients had pre-existing cardiovascular risk factors. Many events were reported to occur during or shortly after sexual intercourse and a few were reported to occur shortly after the use of sildenafil without sexual activity. It is not possible to determine whether these events are related directly to these factors or to other factors. Priapism: Patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia), should consult a doctor before using agents for the treatment of erectile dysfunction, including sildenafil. Prolonged erections and priapism have been occasionally reported with sildenafil in post-marketing experience. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result. Concomitant use with other treatments for erectile dysfunction: The safety and efficacy of combinations of sildenafil with other treatments for erectile dysfunction have not been studied. Therefore the use of such combinations is not recommended. Effects on vision: Cases of visual defects have been reported spontaneously in connection with the intake of sildenafil and other PDE5 inhibitors (see Side Effects). Cases of non-arteritic anterior ischaemic optic neuropathy, a rare condition, have been reported spontaneously and in an observational study in connection with the intake of sildenafil and other PDE5 inhibitors (see Side Effects). Patients should be advised that in the event of any sudden visual defect, they should stop taking VIAGRA CONNECT and consult a physician immediately (see Contra-indications). Concomitant use with CYP3A4 inhibitors: Pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance when co-administered with CYP3A4 inhibitors (such as ketoconazole, itraconazole, erythromycin, cimetidine). Although, no increased incidence of adverse events was observed in these patients, they should be advised to consult a doctor before taking VIAGRA CONNECT as a 25 mg tablet may be more suitable for them (see Precautions). Concomitant use with alpha-blockers: Caution is advised when sildenafil is administered to patients taking an alpha-blocker, as the co-administration may lead to symptomatic hypotension in a few susceptible individuals (see Precautions). This is most likely to occur within 4 hours post sildenafil dosing. In order to minimise the potential for developing postural hypotension, patients should be hemodynamically stable on alpha-blocker therapy prior to initiating sildenafil treatment. Thus, patients taking alpha blockers should be advised to consult their doctor before taking VIAGRA CONNECT as a 25 mg tablet may be more suitable for them. Treatment should be stopped if symptoms of postural hypotension occur, and patients should seek advice from their doctor on what to do. Effect on bleeding: Studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside in vitro. There is no safety information on the administration of sildenafil to patients with bleeding disorders or active peptic ulceration. Therefore the use of sildenafil is not recommended in those patients with history of bleeding disorders or active peptic ulceration, and should only be administered after consultation with a doctor. Hepatic impairment: Patients with hepatic impairment must be advised to consult their doctor before taking VIAGRA CONNECT, since a 25 mg tablet may be more suitable for them (see Dosage and Method of use). Renal impairment: Patients with severe renal impairment (creatinine clearance <30 mL/min), must be advised to consult their doctor before taking VIAGRA CONNECT, since a 25 mg tablet may be more suitable for them (see Dosage and Method of use). Lactose: The film coating of the tablet contains lactose. VIAGRA CONNECT should not be administered to men with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Sodium: This medicinal product contains less than 1 mmol sodium (23 mg) per tablet. Patients on low sodium diets can be informed that this medicinal product is essentially ‘sodium-free’. Use with alcohol Drinking excessive alcohol can temporarily reduce a man’s ability to get an erection. Men should be advised not to drink large amounts of alcohol before sexual activity.

Contra-indications: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Consistent with its known effects on the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway, sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form is therefore contraindicated. Co-administration of VIAGRA CONNECT with ritonavir (a highly potent P450 enzyme inhibitor) is contraindicated (see Precautions). The co-administration of phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see Precautions). Agents for the treatment of erectile dysfunction, including sildenafil, should not be used by those men for whom sexual activity may be inadvisable, and these patients should be referred to their doctor. This includes patients with severe cardiovascular disorders such as a recent (6 months) acute myocardial infarction (AMI) or stroke, unstable angina or severe cardiac failure. Sildenafil should not be used in patients with severe hepatic impairment, hypotension (blood pressure < 90/50 mmHg) and known hereditary degenerative retinal disorders such as retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases). This is because the safety of sildenafil has not been studied in these sub-groups of patients, and its use is therefore contraindicated. Sildenafil is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure. VIAGRA CONNECT should not be used in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease). VIAGRA CONNECT is not indicated for use by women. The product is not intended for men without erectile dysfunction. This product is not intended for men under 18 years of age.

Dosage and Method of use: For Oral Use: Adults: The recommended dose is one 50 mg tablet taken with water approximately one hour before sexual activity. The maximum recommended dosing frequency is once per day. If VIAGRA CONNECT is taken with food, the onset of activity may be delayed compared to the fasted state. Patients should be advised that they may need to take VIAGRA CONNECT a number of times on different occasions (a maximum of one 50 mg tablet per day), before they can achieve a penile erection satisfactory for sexual activity. If after several attempts on different dosing occasions patients are still not able to achieve a penile erection sufficient for satisfactory sexual activity, they should be advised to consult a doctor. Elderly: Dosage adjustments are not required in elderly patients (≥ 65 years old). Renal Impairment: No dosage adjustments are required for patients with mild to moderate renal impairment. However, since sildenafil clearance is reduced in individuals with severe renal impairment (creatinine clearance <30ml/min), individuals previously diagnosed with severe renal impairment must be advised to consult their doctor before taking VIAGRA CONNECT, since a 25 mg tablet may be more suitable for them (see Precautions). Hepatic Impairment: Sildenafil clearance is reduced in individuals with hepatic impairment (e.g. cirrhosis). Individuals previously diagnosed with mild to moderate hepatic impairment must be advised to consult their doctor before taking VIAGRA CONNECT, since a 25 mg tablet may be more suitable for them (see Precautions). The safety of sildenafil has not been studied in patients with severe hepatic impairment, and its use is therefore contraindicated (see Contra-indications). Paediatric population: VIAGRA CONNECT is not indicated for individuals below 18 years of age. Use in patients taking other medicinal products: Pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance when co-administered with CYP3A4 inhibitors (such as ritonavir, ketoconazole, itraconazole, erythromycin, cimetidine). With the exception of ritonavir, for which co-administration with sildenafil is contraindicated (see Contra-indications), individuals receiving concomitant treatment with CYP3A4 inhibitors must be advised to consult their doctor before taking VIAGRA CONNECT, since a 25 mg tablet may be more suitable for them (see Precautions). In order to minimise the potential of developing postural hypotension in patients receiving alpha blocker treatment (e.g. alfuzosin, doxazosin or tamsulosin), patients should be stabilised on alpha blocker therapy prior to initiating sildenafil treatment. Thus, patients taking alpha blockers must be advised to consult their doctor before taking VIAGRA CONNECT since a 25 mg tablet may be more suitable for them (see Precautions). Addition of a single dose of sildenafil to sacubitril/valsartan at steady state in patients with hypertension was associated with a significantly greater blood pressure reduction compared to administration of sacubitril/valsartan alone. Therefore, caution should be exercised when sildenafil is initiated in patients treated with sacubitril/valsartan.

C+D Trade Price (exc VAT) 2 pack £8.82, 4 pack £16.17 and 8 pack £28.39

Date of revision: 04/2023

The SmPC for this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm and from Viatris Medical Information, Building 4, Trident Place, Hatfield Business Park, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL, phone no. 01707 853000,
Email: info.uk@viatris.com